Cargando…
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.(1) This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245054/ https://www.ncbi.nlm.nih.gov/pubmed/35732147 http://dx.doi.org/10.1016/j.xcrm.2022.100668 |